Positive Effects of Biologics on Osteoporosis in Rheumatoid Arthritis|RISS 상세보기

다국어 초록 (Multilingual Abstract)

Osteoporosis is a systemic skeletal disorder that causes vulnerability of bones to fracture owing to reduction in bone density and deterioration of the bone tissue microstructure. The prevalence of osteoporosis is higher in patients with autoimmune inflammatory rheumatic diseases, including rheumatoid arthritis (RA), than in those of the general population. In this autoimmune inflammatory rheumatic disease, in addition to known risk factors for osteoporosis, various factors such as chronic inflammation, autoantibodies, metabolic disorders, drugs, and decreased physical activity contribute to additional risk. In RA, disease-related inflammation plays an important role in local or systemic bone loss, and active treatment for inflammation can help prevent osteoporosis. In addition to conventional synthetic disease-modifying anti-rheumatic drugs that have been traditionally used for treatment of RA, biologic DMARDs and targeted synthetic DMARDs have been widely used. These agents can be employed more selectively and precisely based on disease pathogenesis. It has been reported that these drugs can inhibit bone loss by not only reducing inflammation in RA, but also by inhibiting bone resorption and promoting bone formation. In this review, the pathogenesis and research results of the increase in osteoporosis in RA are reviewed, and the effects of biological agents on osteoporosis are discussed.

번역하기

참고문헌 (Reference)

1 Miao CG, "Wnt signaling pathway in rheumatoid arthritis, with special emphasis on the different roles in synovial inflammation and bone remodeling" 25 : 2069-2078, 2013

2 Ponzetti M, "Updates on osteoimmunology : what's new on the cross-talk between bone and immune system" 10 : 236-, 2019

3 Chen YM, "Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis" 12 : e0188454-, 2017

4 Belizário JE, "Thymic and postthymic regulation of naïve CD4(+)T-cell lineage fates in humans and mice models" 2016 : 9523628-, 2016

5 Weitzmann MN, "The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis" 2013 : 125705-, 2013

6 Ruscitti P, "The role of IL-1β in the bone loss during rheumatic diseases" 2015 : 782382-, 2015

7 Wright NC, "The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine" 29 : 2520-2526, 2014

8 Melton LJ 3rd, "The prevalence of osteoporosis : gender and racial comparison" 69 : 179-181, 2001

9 Bukhari M, "The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis : results from the Norfolk Arthritis Register" 56 : 2929-2935, 2007

10 McInnes IB, "The pathogenesis of rheumatoid arthritis" 365 : 2205-2219, 2011